SUBSCRIBE: Print / eNewsletter
Combined with intensive chemotherapy, the next-generation inhibitor provided excellent results in pediatric patients with Philadelphia chromosome-positive ALL, leading to changes in how this population is treated.
This research found that combining family history and a genetic risk score could better stratify inherited risk for developing prostate cancer.
High-quality patient reported outcomes were observed, suggesting benefits in key aspects of the patient experience with this combination treatment.
These data indicate the need for surveillance and opportunities for intervention in this population.
A recent study indicated that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.
A recent study suggested the activation of apelin/APJ signaling decreased efficacy in VEGF treatment, while bevacizumab decreased disease-free survival rates with increased expression of apelin in patients of ovarian cancer.
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.
Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.
Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.
Research shows that digital videos led to increased knowledge and interventions, but access for vulnerable populations must be improved.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
